JBIO
Price
$7.49
Change
-$0.00 (-0.00%)
Updated
May 22 closing price
Capitalization
235.97M
80 days until earnings call
KLRS
Price
$2.83
Change
-$0.15 (-5.03%)
Updated
May 22 closing price
Capitalization
52.93M
Interact to see
Advertisement

JBIO vs KLRS

Header iconJBIO vs KLRS Comparison
Open Charts JBIO vs KLRSBanner chart's image
Jade Biosciences
Price$7.49
Change-$0.00 (-0.00%)
Volume$2
Capitalization235.97M
Kalaris Therapeutics
Price$2.83
Change-$0.15 (-5.03%)
Volume$71.29K
Capitalization52.93M
JBIO vs KLRS Comparison Chart
Loading...
JBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
KLRS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
JBIO vs. KLRS commentary
May 23, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is JBIO is a Hold and KLRS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
May 23, 2025
Stock price -- (JBIO: $7.49 vs. KLRS: $2.83)
Brand notoriety: JBIO and KLRS are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: JBIO: 0% vs. KLRS: 136%
Market capitalization -- JBIO: $235.97M vs. KLRS: $52.93M
JBIO [@Biotechnology] is valued at $235.97M. KLRS’s [@Biotechnology] market capitalization is $52.93M. The market cap for tickers in the [@Biotechnology] industry ranges from $307B to $0. The average market capitalization across the [@Biotechnology] industry is $2.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

JBIO’s FA Score shows that 1 FA rating(s) are green whileKLRS’s FA Score has 1 green FA rating(s).

  • JBIO’s FA Score: 1 green, 4 red.
  • KLRS’s FA Score: 1 green, 4 red.
According to our system of comparison, both JBIO and KLRS are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

JBIO’s TA Score shows that 3 TA indicator(s) are bullish while KLRS’s TA Score has 4 bullish TA indicator(s).

  • JBIO’s TA Score: 3 bullish, 5 bearish.
  • KLRS’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, KLRS is a better buy in the short-term than JBIO.

Price Growth

JBIO (@Biotechnology) experienced а +1.22% price change this week, while KLRS (@Biotechnology) price change was -20.06% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.79%. For the same industry, the average monthly price growth was +2.82%, and the average quarterly price growth was -2.75%.

Reported Earning Dates

JBIO is expected to report earnings on Aug 11, 2025.

KLRS is expected to report earnings on May 01, 2025.

Industries' Descriptions

@Biotechnology (+0.79% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
JBIO($236M) has a higher market cap than KLRS($52.9M). KLRS YTD gains are higher at: 573.809 vs. JBIO (182.642).
JBIOKLRSJBIO / KLRS
Capitalization236M52.9M446%
EBITDAN/AN/A-
Gain YTD182.642573.80932%
P/E RatioN/AN/A-
RevenueN/AN/A-
Total CashN/AN/A-
Total DebtN/AN/A-
TECHNICAL ANALYSIS
Technical Analysis
JBIOKLRS
RSI
ODDS (%)
Bearish Trend 1 day ago
82%
Bullish Trend 1 day ago
76%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
80%
Momentum
ODDS (%)
Bearish Trend 1 day ago
85%
Bearish Trend 1 day ago
88%
MACD
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 1 day ago
89%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
83%
Bearish Trend 1 day ago
90%
Advances
ODDS (%)
Bullish Trend 4 days ago
81%
Bullish Trend 9 days ago
80%
Declines
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
81%
Bullish Trend 1 day ago
79%
Aroon
ODDS (%)
Bullish Trend 1 day ago
79%
Bearish Trend 1 day ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
JBIO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
KLRS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
LAFVX19.19N/A
N/A
Lord Abbett Affiliated R6
SCAVX13.36N/A
N/A
AB Small Cap Value A
TSMMX14.38N/A
N/A
Nuveen Quant Small/Mid Cap Eq Premier
SJCAX30.18N/A
N/A
Steward Large Cap Core A
GEMQX12.42N/A
N/A
Goldman Sachs Emerging Mkts Eq ex. Chn R

JBIO and

Correlation & Price change

A.I.dvisor indicates that over the last year, JBIO has been closely correlated with OVID. These tickers have moved in lockstep 79% of the time. This A.I.-generated data suggests there is a high statistical probability that if JBIO jumps, then OVID could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To JBIO
1D Price
Change %
JBIO100%
N/A
OVID - JBIO
79%
Closely correlated
+0.35%
KPRX - JBIO
31%
Poorly correlated
-1.26%
SYRE - JBIO
31%
Poorly correlated
+1.96%
VANI - JBIO
26%
Poorly correlated
+0.88%
SLS - JBIO
25%
Poorly correlated
N/A
More

KLRS and

Correlation & Price change

A.I.dvisor indicates that over the last year, KLRS has been loosely correlated with CHRO. These tickers have moved in lockstep 42% of the time. This A.I.-generated data suggests there is some statistical probability that if KLRS jumps, then CHRO could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KLRS
1D Price
Change %
KLRS100%
-5.03%
CHRO - KLRS
42%
Loosely correlated
-3.32%
SPRO - KLRS
21%
Poorly correlated
N/A
MTVA - KLRS
5%
Poorly correlated
N/A
JBIO - KLRS
4%
Poorly correlated
N/A
ASBP - KLRS
4%
Poorly correlated
N/A
More